Neuropsychiatric symptoms of dementia: Are pharmacological treatments effective and safe?

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 1, 2015, Pages 4-

  Ford, Andrew H ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINESTERASE INHIBITOR; CITALOPRAM; MEMANTINE; OLANZAPINE; RISPERIDONE; VALPROIC ACID; PSYCHOTROPIC AGENT;

ALZHEIMER DISEASE; DEMENTIA; DISEASE ASSOCIATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDITORIAL; EVALUATION STUDY; EVIDENCE BASED MEDICINE; HUMAN; MENTAL DISEASE; META ANALYSIS (TOPIC); NEUROPSYCHIATRIC SYMPTOM; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SYMPTOM ASSESSMENT; SYMPTOMATOLOGY; SYSTEMATIC REVIEW (TOPIC); COMPLICATION; MENTAL DISORDERS; PSYCHOLOGY;

ALZHEIMER DISEASE; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS;

EID: 84919770156     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-308420     Document Type: Editorial

References (4)

1. Schneider LS, Tariot PN, Dagerman KS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006;355:1525-38.
2. Wang J, Yu JT, Wang HF, et al. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2015;86:101-9.
3. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005;293:596-608.
4. Porsteinsson AP, Drye LT, Pollock BG, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. JAMA 2014;311:682-91.